# Mortality Risk Scoring Guide: LexisNexis Risk Classifier Uses 2026 Alternative Data

Justin Howard · October 23, 2026

> Do not deploy or price against LexisNexis Risk Classifier mortality scores until a validation pack shows discrimination, calibration, and population definition.

| Takeaway | Detail |
| --- | --- |
| Do not deploy or price against LexisNexis Risk Classifier mortality scores until the vendor supplies a validation pack. | Reader rule: block deployment and pricing until a validation pack is provided. |
| The validation pack must show discrimination, calibration, and population definition. | Required pack contents: discrimination (e.g., AUC/C-statistic), calibration, population definition. |
| LexisNexis Risk Classifier is marketed for mortality-risk stratification using alternative data. | Vendor-marketed capability: mortality-risk stratification using alternative data sources. |
| The public evidence base for LexisNexis Risk Classifier mortality-risk stratification is thin. | Thesis: public evidence base is thin, so the only defensible 2026 action is to demand a documented validation pack. |

This guide covers LexisNexis Risk Classifier mortality-risk stratification using alternative data and the thin public evidence behind it.

It delivers the 2026 rule: demand a validation pack with discrimination, calibration, and population definition before any deployment or pricing.

![Mortality Risk Scoring Guide](https://static.mm-ais.com/article-images-ai/mortality-risk-scoring-guide-lexisnexis-ai-309cf58a.jpg)

## How Risk Classifier Actually Works

LexisNexis Risk Classifier is a mortality-risk stratification product that LexisNexis presents in a Munich Re co-marketed item titled "Stratifying Mortality Risk Using Alternative Data Sources." That co-marketed item is the only grounding evidence that the product exists under that name, so treat the title itself as your first verification anchor: if a sales representative cannot point you to that item, or to an equivalent LexisNexis-hosted page using the same product name, you are not looking at the same offering the marketing describes. A second Munich Re item names a variant, "LexisNexis Risk Classifier with Medical Data," which tells you the product ships in at least two configurations: an alternative-data-only build and a medical-data-augmented build. Before you accept any quote, ask which configuration the pricing covers, because a score built on alternative data alone and a score that also ingests medical data are different inputs feeding the same output label, and a quote that does not name the configuration is not a quote you can compare against anything.

The distinction matters because the two configurations imply different data pipelines, different permissible-use questions, and different validation obligations. Alternative-data-only scoring leans entirely on non-medical sources; adding medical data changes what the model consumes and therefore what a validation pack must document. When you request documentation, name the configuration in writing and require the vendor to confirm it in the response. If the vendor answers with a generic product sheet that does not distinguish the two, treat that as an unresolved item, not as an answer.

Context for who is selling this: LexisNexis is a commercial host specializing in full-text international periodicals, press, and business information, and it is well known in English-speaking markets as a provider of legal-information databases. That is the company's documented core business. Mortality-risk classification is therefore an adjacent, vendor-marketed capability rather than the firm's established line, which is exactly why the burden of proof sits with the vendor rather than with you.

Here is the practical check to run before any deployment or pricing decision. Ask for a validation pack in writing and confirm it contains, at minimum, the following:

| Pack element | What to confirm |
| --- | --- |
| Population definition | The exact cohort the model was validated on, including inclusion and exclusion criteria |
| Outcome definition | How mortality was defined and observed, and over what follow-up |
| Discrimination | AUC or C-statistic reported on that population |
| Calibration | Predicted-versus-observed results, not just a discrimination figure |
| Configuration | Whether results cover alternative-data-only or the medical-data variant |

Run this as a gate, not a conversation. If the pack arrives without a named population, a defined outcome, a discrimination statistic, and calibration results, you have no basis to price against the scores or to deploy them into any decision. Hold the line there: a documented validation pack is the minimum defensible precondition, and until it is in hand, the correct action is to decline to deploy or price against Risk Classifier mortality scores.

![How Risk Classifier Actually Works — Mortality Risk Scoring Guide](https://static.mm-ais.com/article-images-ai/mortality-risk-scoring-guide-lexisnexis-ai-76170006.jpg)

## The Evidence: What Is Actually Sourced

The available sources for this article contain no published performance figures for LexisNexis Risk Classifier. That is the finding, not a gap to paper over. The two Munich Re items surfaced in the source set — "LexisNexis® Risk Classifier - Stratifying Mortality Risk Using Alternative Data Sources" and "LexisNexis® Risk Classifier with Medical Data" — are title-level entries. Neither discloses an AUC or C-statistic, a cohort size, an outcome window, a follow-up period, or a calibration result. If you are being asked to price or deploy against these scores, that absence is the first thing to put in writing.

Run the convergence check yourself before any vendor call. Lay the two Munich Re items side by side and ask what facts appear in both. The answer is narrow: the product name and the alternative-data positioning. The second item confirms a medical-data variant exists; it does not attach a performance metric to that variant. Two items converging on a name and a concept is marketing consistency, not validation. A validation pack, by contrast, converges on numbers — and there are none here to converge on.

| Source item | What it establishes | Performance figure disclosed |
| --- | --- | --- |
| Munich Re — Risk Classifier, alternative data sources | Product name; alternative-data positioning | None in grounding |
| Munich Re — Risk Classifier with Medical Data | Medical-data variant exists | None in grounding |
| Convergent fact across both | Product name; alternative-data premise | None in grounding |

Note what the alternative-data source categories are in this grounding: the items describe alternative data as the input premise but do not enumerate the categories, the contributing data types, or their coverage rates. So the honest statement is that the available sources lists no source categories with any specificity — not that the categories are weak, but that they are unnamed. When you request the validation pack, ask for the source inventory as a line item: which data categories feed the score, what population each covers, and what share of your book would have a match. A vendor that cannot name its inputs cannot defend its outputs.

The practical rule for 2026: treat the title-only evidence as a trigger for a document request, not a basis for a decision. Send the vendor a written ask for four things — population definition, outcome definition, discrimination (AUC or C-statistic with confidence intervals), and calibration (predicted-versus-observed by decile). Set your own internal deadline for the response and hold pricing until it arrives. If the pack comes back with a cohort and an outcome window you can map to your own book, you have something to test. If it comes back as more positioning language, you have your answer, and you have it on the record.

One caution on scope: the LexisNexis corporate figures and the cost-check method belong to a separate part of this analysis, and the alternative-product comparisons belong to another. Keep them out of this section. The claim here is narrow and defensible — zero published performance figures for Risk Classifier in the available sources, and an alternative-data premise stated without named source categories. That is enough to justify the hold.

![The Evidence: What Is Actually Sourced — Mortality Risk Scoring Guide](https://static.mm-ais.com/article-images-pixabay/mortality-risk-scoring-guide-lexisnexis-a6e1d22d.jpg)

## Options Compared: Classifier vs Alternatives

The named LexisNexis-alternative roundups that a 2026 buyer is most likely to land on — Rigorous Themes, Atlassystems, LegesGPT, Vaquill, Aitoolnet, and Spellbook — do not compare anything to Risk Classifier, because none of them are mortality-risk comparisons at all. Rigorous Themes' July 25, 2026 list of "15 Best LexisNexis Alternatives 2026" puts Google Scholar in the number-one slot: a free academic search engine for legal opinions and articles. That is a research tool, not a mortality-risk model, and it cannot substitute for Risk Classifier in any underwriting or pricing workflow. Atlassystems' April 20, 2026 "Top 10 LexisNexis Alternatives" frames its entire comparison around provider data management — a different job-to-be-done than mortality scoring. LegesGPT, Vaquill, Aitoolnet, and Spellbook target case-law research, citator work, and legal-research pricing. The practical check: open each roundup and search the page for "mortality," "risk classifier," "underwriting," or "stratification." If none appear, the list is not evidence about Risk Classifier, and citing it as such in a vendor review or procurement memo is a category error.

That mismatch matters because it means the alternative-data-plus-medical-data variant of Risk Classifier has no named competitor in any of these roundups. A buyer who reads "best alternatives" and assumes a like-for-like mortality model sits behind one of the entries will compare a stratification product against legal-research subscriptions and conclude, wrongly, that the market has been surveyed. It has not.

The second check is whether a roundup states its comparison criteria. Rigorous Themes ranks Google Scholar first on the basis of free access to legal research; Atlassystems ranks on provider data management features. Neither states a mortality-outcome criterion — no discrimination metric, no calibration measure, no population definition. A roundup that never names its outcome cannot validate a mortality model, and a buyer should treat any such list as a starting point for vendor discovery, not as a substitute for a validation pack.

Set the two side by side and the gap is structural, not a matter of degree:

| Roundup (2026) | Stated focus | Mortality-risk comparison? |
| --- | --- | --- |
| Rigorous Themes (Jul 25) | Legal research; Google Scholar ranked first | No |
| Atlassystems (Apr 20) | Provider data management | No |
| LegesGPT | AI legal research for lawyers | No |
| Vaquill | Case-law and citator work | No |
| Aitoolnet | General LexisNexis alternatives | No |
| Spellbook | Legal-platform pricing comparison | No |

The rule that follows is narrow and enforceable: do not treat any of these roundups as a substitute for the validation pack. Before deploying or pricing against Risk Classifier mortality scores, require the vendor to supply discrimination (AUC or C-statistic), calibration, population definition, and outcome definition. If a roundup cannot supply those four items for a named alternative, it has not identified a substitute — it has identified a different product.

![Options Compared: Classifier vs Alternatives — Mortality Risk Scoring Guide](https://static.mm-ais.com/article-images-pixabay/mortality-risk-scoring-guide-lexisnexis-67026a73.jpg)

## Costs and Numbers That Matter

Before you argue about scores, get the vendor's own numbers straight. The German Wikipedia entry on LexisNexis describes a company founded in 1991, seated in Düsseldorf, with roughly 10,500 employees and revenue of about 2 billion. Those figures tell you one thing only: the vendor is large and unlikely to vanish mid-contract. They tell you nothing about what Risk Classifier costs, because corporate revenue is not product pricing.

That distinction matters more than it sounds. A 2 billion revenue line is frequently cited in procurement conversations as if it implies premium pricing or, conversely, as if it implies the vendor can absorb a discount. Neither inference is supported. Scale is a stability signal, not a price signal, and you should refuse to let it enter the negotiation as either.

Here is the harder fact: nowhere in the available grounding does a per-score, per-life, or per-policy price for Risk Classifier appear. Not in the Munich Re co-marketed items, not in the LexisNexis alternatives roundups from Rigorous Themes, Atlassystems, LegesGPT, Vaquill, Aitoolnet, or Spellbook. If someone on your team has a number in a slide, ask where it came from. If the answer is "an estimate," treat it as zero.

So check cost by mechanism, not by assumption. Request a written quote that forces the vendor to commit to four things:

| Quote element | What you are forcing into writing |
| --- | --- |
| Unit of charge | Per life scored, or per portfolio run — these are not interchangeable |
| Minimum volume | Any floor below which pricing changes or the contract does not apply |
| Medical-data variant | Whether the medical-data version is priced separately from the alternative-data version |
| Term and renewal basis | Whether the rate holds for the term or resets at renewal |

Pair that quote request with the validation pack demand. A price without a documented population definition, outcome definition, discrimination statistic, and calibration check is not a price you can underwrite against — it is a number attached to an unmeasured product. Get both documents in the same request so the vendor cannot sequence them.

One rule closes this section: if the quote arrives without a stated unit of charge, send it back. An unpriced unit is how per-portfolio costs quietly become per-life costs at invoice time.

![Costs and Numbers That Matter — Mortality Risk Scoring Guide](https://static.mm-ais.com/article-images-pixabay/mortality-risk-scoring-guide-lexisnexis-1cc1a7fb.jpg)

## What the Evidence Does NOT Establish

The most important thing to understand about LexisNexis Risk Classifier is what its public evidence base does not contain. The Munich Re co-marketed item titled "Stratifying Mortality Risk Using Alternative Data Sources" is the only grounding evidence that the product exists and does what its name suggests. That item does not publish a single discrimination statistic. No AUC, no C-statistic, no Gini coefficient, and no lift figure for Risk Classifier appears anywhere in the available sources. Discrimination is therefore unverified: you cannot know from the public record whether the score separates high-mortality from low-mortality lives any better than chance, let alone better than a simple age-and-sex table.

Discrimination is also only half the validation story, and the missing half is the one that matters most for pricing. No calibration table appears in the available sources — nothing showing predicted mortality against observed mortality by score decile. This distinction is not academic. A score can rank lives correctly and still be miscalibrated: if the top decile is predicted at three times the portfolio average but actually runs at 1.5 times, a carrier that prices off the predicted figure overcharges that segment and misprices every other decile in the opposite direction. Ranking without calibration supports triage; it does not support a mortality assumption. Before deploying, demand a decile-level predicted-versus-actual table with confidence intervals, and check whether the calibration was fit on the same population you intend to price.

Population definition is the third missing dimension. The available sources contains no study population description for Risk Classifier — no age band, no impairment mix, no geography, no distribution channel, no observation period. Without that, domain transfer from whatever cohort the vendor used to your book is unproven. A model validated on a broad, near-issue-age population may behave very differently on a simplified-issue or older-age block, and a model built on one channel may not transfer to another. Ask for the inclusion and exclusion criteria, the age range, the impairment prevalence, and the geographic and channel composition of the validation sample, then compare each against your own in-force profile.

Outcome definition and outcome window are the fourth and fifth missing dimensions. The available sources never states how death was ascertained, over what follow-up period, or with what censoring rule. A one-year mortality outcome and a ten-year outcome are different products, and a score validated against a short window can decay sharply when applied to a longer one. Require the outcome definition, the follow-up window, the censoring approach, and the effective sample size at each horizon.

Where the rule breaks: thin or unrepresentative validation cells, populations that differ materially from the vendor cohort, and any pricing use that depends on absolute mortality levels rather than rank order. In those edge cases, the absence of a validation pack is not a documentation gap — it is a reason not to deploy.

![What the Evidence Does NOT Establish — Mortality Risk Scoring Guide](https://static.mm-ais.com/article-images-pixabay/mortality-risk-scoring-guide-lexisnexis-23bae424.jpg)

## Validation Pack Request

The validation pack is the deliverable you request in writing, and it is the only artifact that should move a mortality-risk decision forward. Build the request around three inputs you already control: your in-force cohort definition (issue years, age band, face-amount band), your observed mortality outcome window, and your current baseline table. Send those three items to the vendor and ask for every performance figure to be reported on that cohort, not on a generic book. A vendor that cannot or will not match your cohort definition has told you something useful before you spend a dollar on deployment.

Checkpoint 1 — discrimination. Ask for the C-statistic (AUC) computed on a cohort matching your age band, with the outcome definition and follow-up window stated in the same document. If the vendor cannot produce a C-statistic on a matched cohort, stop. Do not accept a qualitative claim that the score "stratifies risk," and do not accept a figure computed on a different age band and carried over as if it transfers. Discrimination is the first gate because a score that cannot rank order risk within your population cannot inform pricing or underwriting selection, no matter how rich the underlying data sources are.

Checkpoint 2 — calibration. Ask for predicted-versus-actual mortality by decile over a stated window, with the decile boundaries and the exposure basis disclosed. If that table is absent, stop. Discrimination without calibration tells you the score sorts people; it does not tell you whether the predicted level is right, and a misleveled score is worse than no score when it feeds a pricing table. Require the decile table on your cohort definition, not a national sample, and require the window to be stated so you can judge whether the experience period resembles the one you are underwriting.

Checkpoint 3 — population definition and stability. Ask for the inclusion and exclusion rules behind the validation cohort, the alternative-data coverage rate within it, and whether performance was re-measured after any material change to the input sources. If the population definition is missing or the coverage rate is undisclosed, stop. A validation pack that does not say who was in the cohort cannot be replicated, and an unreplicable pack is a marketing document, not evidence.

| Checkpoint | Request | Stop rule |
| --- | --- | --- |
| 1. Discrimination | C-statistic (AUC) on a cohort matching your age band | Absent → stop |
| 2. Calibration | Predicted vs. actual mortality by decile over a stated window | Absent → stop |
| 3. Population | Inclusion/exclusion rules, alternative-data coverage rate, re-measurement after source changes | Undisclosed → stop |

Put the request in writing, give the vendor your three inputs, and hold the line at each checkpoint. The public evidence base for this capability is thin enough that the burden sits with the vendor, and a documented pack is the only thing that shifts it.

## Decision Rules

The decision rules below convert the evidence gap into five if/then gates. Apply them in order; each gate is a stop-or-proceed test, not a suggestion. The canonical rule — do not deploy or price against LexisNexis Risk Classifier mortality scores until the vendor supplies a validation pack showing discrimination, calibration, population definition, and outcome definition — is the spine, and these rules are how you enforce it in practice.

**Rule 1 — Full validation pack, matched cohort: proceed to limited pilot.** If the vendor supplies a C-statistic (or AUC) and a calibration table on a cohort that matches your book on age band, impairment mix, and outcome definition, then proceed to a limited pilot with shadow scoring. Shadow scoring means the score runs alongside your existing underwriting or pricing process, is logged, and is not used to set rates or make decisions. Set the pilot's success criteria before you start: a pre-declared discrimination floor, a calibration check (predicted versus observed mortality by decile), and a review of the population definition against your own book. If the pack clears those criteria, you have grounds to expand; if it does not, you stop at shadow mode.

**Rule 2 — Marketing-only evidence: triage flag only, never a pricing input.** If the vendor supplies only a product name and marketing positioning — as in the available sources, where the only surfaced items are the Munich Re co-marketed "LexisNexis® Risk Classifier - Stratifying Mortality Risk Using Alternative Data Sources" and the "LexisNexis® Risk Classifier with Medical Data" variant — then treat the score as a triage flag and never as a pricing input. A triage flag can route a file for manual review or order a conventional medical requirement; it cannot move a rate, a reserve, or a class assignment. Document that restriction in the model governance file so the flag does not drift into pricing use by default.

**Rule 3 — Cohort mismatch: re-weight or re-validate before any pricing use.** If the study cohort differs from your book on age band or impairment mix, then re-weight or re-validate before any pricing use. Mismatch is the most common failure mode: a C-statistic computed on a cohort with a different age distribution or impairment prevalence does not transfer to your book without adjustment. Ask for the cohort's age-band distribution and impairment prevalence, compare them to your own, and either re-weight the validation results or commission a fresh validation on your population. Until that is done, the score stays in triage.

**Rule 4 — Missing calibration: no pricing use, regardless of discrimination.** If the vendor supplies discrimination but no calibration table, then the score cannot support pricing even if the C-statistic looks strong. Discrimination tells you the score ranks risk; calibration tells you whether the predicted mortality level is right. Pricing needs both. Request observed-versus-expected mortality by score decile; if the vendor cannot supply it, the score remains a ranking tool only.

**Rule 5 — No outcome definition: no validation claim at all.** If the vendor does not state the outcome definition — what event, over what horizon, measured how — then no validation claim can be evaluated, and the score stays out of both pricing and formal triage design. Outcome definition is the anchor for every other number; without it, a C-statistic is uninterpretable. Ask for it in writing, and treat a refusal or a vague answer as a stop signal.

| Gate | Condition | Action |
| --- | --- | --- |
| 1 | C-statistic + calibration on matched cohort | Limited pilot, shadow scoring |
| 2 | Marketing positioning only | Triage flag; never pricing |
| 3 | Cohort differs on age band or impairment mix | Re-weight or re-validate first |
| 4 | Discrimination without calibration | No pricing use |
| 5 | No outcome definition | No validation claim; no use |

## What to do next

| Step | Action | Why it matters |
| --- | --- | --- |
| 1 | Send LexisNexis a written request for the validation pack on LexisNexis Risk Classifier mortality scores, specifying the four required contents: discrimination (e.g., AUC/C-statistic), calibration, population definition, and outcome window. | Without these four items, the score cannot be evaluated against your book, and the public evidence base for the mortality-risk stratification capability remains thin. |
| 2 | Require that the population definition and outcome window in the pack describe a cohort matching your book, not a generic or undisclosed population. | A score validated on a non-matching cohort does not transfer; discrimination and calibration figures are only meaningful on a comparable population. |
| 3 | Instruct pricing and underwriting teams to block any deployment or pricing against LexisNexis Risk Classifier mortality scores until the pack is received and reviewed. | This is the canonical decision rule: no validation pack, no pricing input. |
| 4 | If the score is already in use, downgrade it to a triage flag only — never a pricing input — and document that status. | Treating the score as a triage flag preserves any operational signal while removing the unpriced risk of an unvalidated mortality score. |
| 5 | Log the vendor's response (or non-response) to the validation-pack request, and re-review the block status when the pack arrives. | The block is conditional, not permanent; the documented request creates the audit trail for lifting it once discrimination, calibration, population definition, and outcome window are supplied. |

## Frequently Asked Questions

**What must happen before deploying or pricing against these mortality scores?**

Do not deploy or price against LexisNexis Risk Classifier mortality scores until the vendor supplies a validation pack.

**What must a validation pack show?**

The validation pack must show discrimination, calibration, and population definition.

**What capability is LexisNexis marketing?**

LexisNexis Risk Classifier is marketed for mortality-risk stratification using alternative data.

**How is the public evidence base described?**

The public evidence base for LexisNexis Risk Classifier mortality-risk stratification is thin.

**Where is the product presented?**

LexisNexis Risk Classifier is a mortality-risk stratification product that LexisNexis presents in a Munich Re co-marketed item titled "Stratifying Mortality Risk Using Alternative Data Sources."

**What does this guide cover?**

This guide covers LexisNexis Risk Classifier mortality-risk stratification using alternative data and the thin public evidence behind it.

## Quick answers

| What should readers do before deploying or pricing against LexisNexis Risk Classifier mortality scores? | Do not deploy or price against LexisNexis Risk Classifier mortality scores until the vendor supplies a validation pack. |
| --- | --- |
| What must the validation pack show? | The validation pack must show discrimination, calibration, and population definition. |
| What is LexisNexis Risk Classifier marketed for? | LexisNexis Risk Classifier is marketed for mortality-risk stratification using alternative data. |
| How is the public evidence base described? | The public evidence base for LexisNexis Risk Classifier mortality-risk stratification is thin. |
| What does the guide deliver? | It delivers the 2026 rule: demand a validation pack with discrimination, calibration, and population definition before any deployment or pricing. |

Also worth reading: **LexisNexis Risk Solutions: What Your Data Profile Reveals and How It's Used**: [LexisNexis Risk Solutions: What Your](https://legalpdf.io/blog/lexisnexis_risk_solutions_what_your_data_profile_reveals_and_how_its_used.php) · **LexisNexis Risk Solutions Integrates Advanced AI Models into eDiscovery Platform Analysis of 2024 Implementation Results Shows 47% Improvement in Document Review Accuracy**: [LexisNexis Risk Solutions Integrates Advanced](https://legalpdf.io/blog/lexisnexis_risk_solutions_integrates_advanced_ai_models_into.php) · **LexisNexis Customer Support Data Integration Analysis of Response Times and Resolution Rates in Contract Review Workflows (2024)**: [LexisNexis Customer Support Data Integration](https://legalpdf.io/blog/lexisnexis_customer_support_data_integration_analysis_of_res.php)

### Related reading

- [LexisNexis Customer Support Data Integration Analysis of Response Times and Resolution Rates in Contract Review Workflows (2024)](https://legalpdf.io/blog/lexisnexis_customer_support_data_integration_analysis_of_res.php)
- [LexisNexis Risk Solutions Integrates Advanced AI Models into eDiscovery Platform Analysis of 2024 Implementation Results Shows 47% Improvement in Document Review Accuracy](https://legalpdf.io/blog/lexisnexis_risk_solutions_integrates_advanced_ai_models_into.php)
- [LexisNexis Risk Scores AI's Controversial Role in Legal Decision-Making](https://legalpdf.io/blog/lexisnexis_risk_scores_ai_s_controversial_role_in_legal_deci.php)
- [The Conundrum of LexisNexis Data Hindering Home Insurance Coverage](https://legalpdf.io/blog/the_conundrum_of_lexisnexis_data_hindering_home_insurance_co.php)
- [California's Confidential Marriage License A Lesser-Known Alternative to Public Marriage Records](https://legalpdf.io/blog/california_s_confidential_marriage_license_a_lesser_known_al.php)
- [Evaluating Modern AI Legal Research Tools Beyond LexisNexis](https://legalpdf.io/blog/evaluating_modern_ai_legal_research_tools_beyond_lexisnexis.php)

### Latest

- [Rand v. Claremont: Verify Funding Options Before Committing](https://legalpdf.io/blog/rand-v-claremont-verify-funding-options-before-committing.php)
- [How Courts Use Complexity: 35 Years NP-Complete Citations, Cite/Ignore](https://legalpdf.io/blog/how-courts-use-complexity-35-years-np-complete-citations-citeignore.php)
- [How to Verify NER Clause-Extraction Benchmarks on 2024 SEC 10-K Risk Factors](https://legalpdf.io/blog/how-to-verify-ner-clause-extraction-benchmarks-on-2024-sec-10-k-risk-factors.php)

Canonical: https://legalpdf.io/blog/mortality-risk-scoring-guide-lexisnexis-risk-classifier-uses-2026-alternative-data.php
Markdown: https://legalpdf.io/blog/mortality-risk-scoring-guide-lexisnexis-risk-classifier-uses-2026-alternative-data.php/index.md